Welcome to CDC stacks | Metformin Prescription for Insured Adults With Prediabetes From 2010 to 2012 - 36898 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
Clear All Simple Search
Advanced Search
Metformin Prescription for Insured Adults With Prediabetes From 2010 to 2012
Filetype[PDF-439.31 KB]

  • Pubmed ID:
  • Pubmed Central ID:
  • Description:

    Prediabetes affects 1 in 3 Americans. Both intensive lifestyle intervention and metformin can prevent or delay progression to diabetes. Over the past decade, lifestyle interventions have been translated across various settings, but little is known about the translation of evidence surrounding metformin use.


    To examine metformin prescription for diabetes prevention and patient characteristics that may affect metformin prescription.


    Retrospective cohort analysis over a 3-year period.


    Employer groups that purchased health plans from the nation’s largest private insurer.


    A national sample of 17 352 working-age adults with prediabetes insured for 3 continuous years between 2010 and 2012.


    Percentage of health plan enrollees with prediabetes who were prescribed metformin.


    Only 3.7% of patients with prediabetes were prescribed metformin over the 3-year study window. After adjustment for age, income, and education, the predicted probability of metformin prescription was almost 2 times higher among women and obese patients and more than 1.5 times higher among patients with 2 or more comorbid conditions.


    Missing data on lifestyle interventions, possible mis-classification of prediabetes and metformin use, and inability to define eligible patients exactly as defined in the American Diabetes Association guidelines.


    Evidence shows that metformin is rarely prescribed for diabetes prevention in working-age adults. Future studies are needed to understand potential barriers to wider adoption of this safe, tolerable, evidence-based, and cost-effective prediabetes therapy.

    Primary Funding Source

    Centers for Disease Control and Prevention (Division of Diabetes Translation) and the National Institute of Diabetes and Digestive and Kidney Diseases.

  • Document Type:
  • Collection(s):
  • Funding:
    K08-AG033360/AG/NIA NIH HHS/United States
    P30 AG021684/AG/NIA NIH HHS/United States
    P30-AG021684/AG/NIA NIH HHS/United States
    U58 DP002722/DP/NCCDPHP CDC HHS/United States
    U58DP002722-05/DP/NCCDPHP CDC HHS/United States
    UL1 TR000124/TR/NCATS NIH HHS/United States
    UL1TR000124/TR/NCATS NIH HHS/United States
No Related Documents.
You May Also Like: